SK pharmteco Announces $260 Million Expansion in South Korea to Boost Peptide and Small Molecule Production
Slice of Healthcare Team
10/02/2024
Key Highlights
- $260 million investment for new state-of-the-art production facility in Sejong, South Korea.
- Facility will feature eight production trains and produce tens of metric tons annually.
- Includes cutting-edge peptide R&D facilities and cGMP labs for clinical and commercial production.
- Hiring over 300 employees to support the expansion by late 2026.
- Addresses global demand for small molecules and peptides in life-saving therapies.
Source: Business Wire
Notable Quotes
“ This expansion is a testament to our unwavering dedication to serving the evolving needs of the life sciences industry. ”
Joerg Ahlgrimm, CEO at SK pharmteco
“ By expanding our capacity and capabilities, we can offer even faster turnaround times, increased flexibility, and a higher level of quality. ”
Yongwoo Park, President, Small Molecule, Asia at SK pharmteco
